N/A N=5 Otolith Function in Patients With Primary Ciliary Dyskinesia
Primary Ciliary Dyskinesia
Primary: Vestibular Evoked Myogenic Potentials (VEMPs) — 0; 3; 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=100 A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.
Lymphocytic Leukemia, Chronic
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) — 99 percentage of participants
Phase 2 N=77 OIT and Xolair® (Omalizumab) in Cow's Milk Allergy
Milk Allergy
Primary: Percentage of Subjects in the Xolair® (Omalizumab) Group vs. Placebo Group Developing Clinical Tolerance to Milk — 46.4; 34.5 Percent of participants — p=0.42
Phase 2 N=72 A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction
Methamphetamine Dependence, Treatment Seeking
Primary: Methamphetamine Abstinence
Phase 2 N=67 A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy
Prostate Cancer
Primary: Percentage of Participants With a Prostate-Specific Antigen (PSA) Response at Week 25 — 92.5 Percentage of Participants
Phase 4 N=100 Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
Coronary Artery Disease
Primary: Thrombin Generation Test: Baseline — 1810; 1682 nM*minutes
Phase 4 N=169 Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
Diabetes Mellitus, Type 2 · Hypertension
Primary: Change From Baseline in the Mean 24-Hour Systolic Blood Pressure (SBP) to Week 6 — 136.7; 136.5; 139.6; -1.26 millimeter of mercury (mmHg) — p=0.062
Phase 3 N=351 A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia
Anemia
Primary: Percentage of Participants Maintaining Mean Hemoglobin Concentration Within Plus or Minus (+/-) 1 Gram Per Deciliter (g/dL) of Reference and Within the Target Range…
Phase 2 N=57 Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) Based on the Assessments by Investigator — 8.8; 36.8; 45.6 percentage of participants
Phase 1 N=42 A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)
Chronic Hepatic Impairment
Primary: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Time of the Last Quantifiable Concentration (AUC 0-t) of Preladenant After a Single Dose of…
Phase 3 N=105 Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Dry Eye Syndrome
Primary: Global Ocular Staining (With Oxford Scale - Ranges : 0-15) — -2.5; -2.7 score on a scale
Phase 3 N=184 A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis
Anemia
Primary: Percentage of Participants With Both Hemoglobin Values of the Evaluation Phase in the Range of 11-12 Grams Per Deciliter (g/dL) — 10.67 percentage of participants
N/A N=23 High Water Intake to Slow Progression of Polycystic Kidney Disease
Kidney, Polycystic, Autosomal Dominant
Primary: Change in Urine cAMP Concentration and Urine Osmolality (UOsm) — -2.6; -2.0 fold change in cAMP/UOsm (umol/UOsm)
N/A N=20 Task-oriented Training for Stroke: Impact on Function Mobility
Cerebrovascular Accident · Stroke
Primary: Economy of Gait — 13.44; 12.67 ml/kg/min
Phase 2 N=25 A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 16 Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale — 55.2; 59.0…